Walder Wyss advises FC Capital Fund I, L.P., Shanghai, as investor in connection with Cellestia’s recent financing round. Cellestia was founded in 2014 as a spin-off from EPFL (Ecole Polytechnique Fédérale de Lausanne).
Its pipeline including lead candidate, oral small molecule CB-103 is based on proprietary know-how and more than two decades of research at Swiss Institute for Experimental Cancer Research (ISREC) at EPFL.
The Walder Wyss team included Alexander Gutmans (Partner, Corporate, Venture Capital, in picture), Stefano Codoni (Partner, IP Life Sciences), Robert von Rosen (Partner, Corporate M&A), Jessica Aeschbach Flórez (Associate, Corporate) as well as Vanessa C. Haubensak (Associate, Corporate).
Involved fees earner: Jessica Aeschbach Flórez – Walder Wyss Ltd.; Stefano Codoni – Walder Wyss Ltd.; Alexander Gutmans – Walder Wyss Ltd.; Vanessa Haubensak – Walder Wyss Ltd.; Robert von Rosen – Walder Wyss Ltd.;
Law Firms: Walder Wyss Ltd.;
Clients: FC Capital Fund I, L.P.;